Compare Bristol-Myers Squibb Co (BMY) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wayfair Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Wayfair Inc trades at $103.55 (market cap $14.14B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.2× Wayfair Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| BMY | W | |
|---|---|---|
Market Cap | $129.94B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $119.05 |
52-Week Low | $42.60 | $57.40 |
Enterprise Value | $163.92B | $16.48B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wayfair (W) trades at $106.59, up 2.44% today, showing strong momentum following better-than-expected Q2 2026 earnings. Technical indicators signal a bullish trend with the stock approaching key resistance levels. Fundamentally, the company delivered 7.5% year-over-year revenue growth in Q2 2026, though it continues to operate at a net loss margin of -2.49%. Recent news highlights strong U.S. segment performance and market share gains despite international challenges.
The outlook remains cautiously optimistic with analysts projecting 51.78% buy ratings and a $122 consensus price target, representing 14.4% upside potential. Key risks include persistent unprofitability, high debt-to-asset ratio of 95.11%, and uneven consumer demand. The stock's premium valuation at 151.17x EV/EBITDA requires continued execution on growth and margin expansion targets to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
